patients

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Health

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in…

3 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Health

HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

January 13, 2025 23:00 ET | Source: HUTCHMED (China) Limited — Indication expands to include treatment-naïve patients — — The 2021…

3 months ago

SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS LEADERSHIP CHANGE: CHARLES NOLET TO SUCCEED ATTILA BORBATH AS CEO

Health

SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS LEADERSHIP CHANGE: CHARLES NOLET TO SUCCEED ATTILA BORBATH AS CEO

Brussels, January 13, 2025. Synergia Medical SA, a leader in developing optoelectronic medical devices, is pleased to announce the successful…

3 months ago

HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

Health

HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…

4 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million

Health

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million

December 23, 2024 19:22 ET | Source: PolyPid Ltd. • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in…

4 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old

Health

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

4 months ago